Speaking at #CCC2026, the researcher walks through what GLP-1 drugs for diabetes and weight loss do. Shared by the Canadian Cardiovascular Society.
Recap by typeshit. Post by Facebook on Facebook.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
Reddy points to coverage cuts in Maine and Michigan and cites a study estimating $192,735 in lifetime medical savings for GLP-1 users aged 40 to 50.
Health law researcher Tim Caulfield tells Global News that, beyond GLP-1s, popular peptides lack good evidence. Health Canada has also warned about contaminated unauthorized products.
Loading…